Ablaze Pharmaceuticals Raises $75M via Series A Financing
Executive Summary
Ablaze Pharmaceuticals (focused on the development and commercialization of innovative targeted radiopharmaceutical therapies (TRT) against tumor targets) raised a $75M Series A financing round. The financing was co-led by Vivo Capital and AdvanTech Capital with participation from RAYZ Investments, Nan Fung Life Sciences, Pivotal bioVenture Partners China, venBio Partners, Samsara BioCapital and Venrock Healthcare Capital Partners. Proceeds from the Series A financing will support Ablaze's establishment of a pipeline of advanced TRT candidates for the treatment of solid tumors, expansion of its leadership team, building up infrastructure for radiopharmaceuticals, and securing further strategic collaborations.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice